Innate Pharma S.A. (IPHA)

NASDAQ: IPHA · IEX Real-Time Price · USD
2.84
-0.06 (-2.07%)
Jul 5, 2022 4:30 PM EDT - Market closed

Income Statement (Annual)

Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Year 20212020201920182017
Revenue
24.769.7785.4593.9544.03
Revenue Growth (YoY)
-64.59%-18.34%-9.05%113.37%-
Gross Profit
24.769.7785.4593.9544.03
Selling, General & Admin
25.5218.9920.9818.1417.02
Research & Development
4749.7162.969.5667
Other Operating Expenses
0001.110
Operating Expenses
72.5368.6983.8788.8184.02
Operating Income
-47.831.081.585.15-39.98
Interest Expense / Income
46.764.988.4310.54
Other Expense / Income
0.9958.317.36-6-2.5
Pretax Income
-52.81-63.98-20.762.72-48.02
Income Tax
000-0.330.37
Net Income
-52.81-63.98-20.763.05-48.39
Net Income Common
-52.81-63.98-20.763.05-48.39
Shares Outstanding (Basic)
7979755954
Shares Outstanding (Diluted)
---5954
Shares Change
---8.14%-
EPS (Basic)
-0.66-0.81-0.310.05-0.89
EPS (Diluted)
-0.66-0.81-0.310.05-0.89
Free Cash Flow Per Share
-0.75-0.670.45-0.57-0.94
Gross Margin
100.00%100.00%100.00%100.00%100.00%
Operating Margin
-193.60%1.55%1.84%5.48%-90.80%
Profit Margin
-213.78%-91.70%-24.29%3.25%-109.88%
Free Cash Flow Margin
-240.37%-75.48%39.38%-35.55%-115.76%
Effective Tax Rate
0.00%0.00%0.00%-12.26%-0.77%
EBITDA
-44.22-0.420.7518.55-33.09
EBITDA Margin
-178.99%-0.61%0.87%19.74%-75.15%
Depreciation & Amortization
4.656.816.537.44.39
EBIT
-48.81-57.22-15.7811.15-37.48
EBIT Margin
-197.59%-82.01%-18.47%11.86%-85.12%
Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).